^
    4d
    A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=154, Active, not recruiting, Viridian Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    VRDN-001
    18d
    A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=212, Not yet recruiting, Viridian Therapeutics, Inc.
    New P3 trial
    |
    VRDN-001
    2ms
    An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies (clinicaltrials.gov)
    P3, N=143, Recruiting, Viridian Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Feb 2023
    Enrollment open • Trial initiation date
    |
    VRDN-001
    4ms
    Study of ZB001 in Chinese Patients With Thyroid Eye Disease (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Zenas BioPharma (USA), LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    VRDN-001
    5ms
    An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies (clinicaltrials.gov)
    P3, N=143, Not yet recruiting, Viridian Therapeutics, Inc.
    New P3 trial
    |
    VRDN-001
    5ms
    Study of ZB001 in Chinese Patients With Thyroid Eye Disease (clinicaltrials.gov)
    P1, N=16, Recruiting, Zenas BioPharma (USA), LLC | N=24 --> 16
    Enrollment change
    |
    VRDN-001
    7ms
    A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=159, Recruiting, Viridian Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    VRDN-001
    8ms
    Poly-l-glutamic acid modification modulates the bio-nano interface of a therapeutic anti-IGF-1R antibody in prostate cancer. (PubMed, Biomaterials)
    PGA conjugation also enhances AVE1642's anti-tumor activity in an orthotopic prostate cancer mouse model, while PGA-AVE1642 induces more significant suppression of cancer cell proliferation/angiogenesis than AVE1642. These findings demonstrate that PGA conjugation modulates an antibody's bio-nano interface, mechanism of action, and therapeutic activity.
    Journal
    |
    VRDN-001